A review of cost–effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert review of pharmacoeconomics & outcomes research

• Publication date

  2013-08-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1586/14737167.2013.814937PMID 23977974
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal

  2013cited by this paper
• Health economic decision-making: a comparison between UK and Spain.

  2012cited by this paper
• Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions.

  2012cited by this paper
• Certolizumab pegol for the treatment of rheumatoid arthritis

  2011influential reference
• Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

  2011cited by this paper
• The pathogenesis of rheumatoid arthritis.

  2011cited by this paper
• Quantifying the economic burden of productivity loss in rheumatoid arthritis.

  2011cited by this paper
• The burden of illness of rheumatoid arthritis

  2011cited by this paper
• PR1 Key Market Access Drivers for A Successful Health Technology Appraisal outcome – The Case of Rheumatoid Arthritis

  2011cited by this paper
• Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs

  2010influential reference
• Tocilizumab for the treatment of rheumatoid arthritis

  2010influential reference
• The impact of health technology assessments: an international comparison

  2010cited by this paper
• Rheumatoid arthritis

  2010cited by this paper
• Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

  2010cited by this paper
• Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.

  2009cited by this paper
• Ensuring value for money in health care: the role of health technology assessment in the European Union

  2008cited by this paper
• The pathogenesis of rheumatoid arthritis.

  2007cited by this paper
• The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments

  2007cited by this paper
• Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis

  2006cited by this paper
• Health technology assessment : an introduction to objectives, role of evidence, and structure in Europe

  2005cited by this paper
• The Iterative Use of Economic Evaluation as Part of the Process of Health Technology Assessment

  1997cited by this paper
• [Rheumatoid arthritis].

  1983cited by this paper

• Cost-minimization analysis of biological disease-modifying antirheumatic drugs in the Brazilian public health system (SUS) considering patients’ weight

  2019cites this paper
• Tailored approach to rheumatoid arthritis treatment with TNF inhibitors: where do we stand?

  2018cites this paper
• A Novel Approach for Integrating Best Evidence and Patient Preferences into Treatment Recommendations for Rheumatoid Arthritis

  2016cites this paper
• Links between Pharmaceutical R&D Models and Access to Affordable Medicines

  2016cites this paper
• Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece

  2015cites this paper
• Access to an optimal treatment. Current situation

  2015cites this paper
• Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis.

  2015cites this paper
• Clinicoeconomics and Outcomes Research Dovepress Annual Biologic Treatment Cost for New and Existing Patients with Moderate to Severe Plaque Psoriasis in Greece

  year unknowncites this paper
• Clinicoeconomics and Outcomes Research Dovepress Economic Evaluation of Anti-tnf Agents for Patients with Rheumatoid Arthritis in Greece

  year unknowncites this paper
• Clinicoeconomics and Outcomes Research Dovepress Costs Associated with Rheumatoid Arthritis in Italy: Past, Present, and Future

  year unknowncites this paper